PierianDx and Syapse are combining their respective products to provide an end-to-end genomic testing workflow for hospitals' pathology laboratories.

The partners will integrate PierianDx's Clinical Genomicist Workstation and Syapse's Precision Medicine platform. The PierianDx platform will help these labs streamline test ordering and results delivery while Syapse's platform will enable labs to integrate the results of molecular tests with clinical data from electronic health records, and provide physicians with molecularly informed decision support at the point of care.

Customers will also be able access to the PierianDx Collaborative Knowledgebase from the Syapse platform, the partners said. The knowledgebase provides access to curated publications, biological information, computational predictions, population frequency data, clinical research and trial correlations, and disease variants reported in clinical databases. Access to this information will provide clinicians with meaningful insights into patient-specific disease conditions.

"This partnership offers the best of both worlds to our clients," Ted Briscoe, PierianDx's CEO, said in a statement. It provides "a powerful solution to advance patient care and treatment."

"As genomic testing becomes a routine part of cancer care, healthcare provider systems are increasingly implementing molecular profiling testing services within their internal pathology laboratories," Jonathan Hirsch, Syapse's founder and president, added. "Our partnership with PierianDx will supply healthcare systems' in-house labs with a simpler and more integrated workflow."